Nutritional interventions and dietary supplementation for mitochondrial disease patients
Prof. Marni J. Falk from University of Pennsylvania Perelman School of Medicine, USA will talk about "Nutritional interventions and dietary supplementation for mitochondrial disease patients" during the 9th World Congress on Targeting Mitochondria, which will be held at Steigenberger Hotel, Berlin on October 23-25, 2018.
Talk Summary: "Mitochondrial diseases are a collectively common group of inherited metabolic disorders with extensive genetic, biochemical, and clinical heterogeneity that share impaired energy production capacity. Resulting secondary cellular adaptations predictably occur that substantially alter diverse aspects of nutrient processing and intermediary metabolism. Limited knowledge, with no therapeutic guidelines, currently exists regarding the use of dietary modification to improve health in mitochondrial disease patients. Furthermore, the clinical implementation of either macromolecular nutrient modification or dietary supplements has been highly variable and poorly studied."
For more information, please visit www.targeting-mitochondria.com
Mechanism and therapeutic potential of cyclophilin inhibitors for prevention of mitochondrial myopathy progression
Prof. Håkan Westerblad from the Karolinska Intitutet, Stockholm, Sweden will give a presentation about “Mechanism and therapeutic potential of cyclophilin inhibitors for prevention of mitochondrial myopathy progression” during the next 9th World Congress on Targeting Mitochondria, which will be held at Steigenberger Hotel, Berlin on October 23-25, 2018.
According to Prof. Håkan Westerblad: "Mice with skeletal muscle-specific disruption of the mitochondrial transcription factor A (Tfam), Tfam knock-out (KO) mice, develop a lethal mitochondrial myopathy. We have identified excessive mitochondrial Ca2+ uptake as a likely trigger of muscle dysfunction in Tfam KO mice. The expression of the mitochondrial protein PPIF (also called cyclophilin D) is increased in muscles of TFam KO mice as well as in patients with mitochondrial myopathy. The cyclophilin inhibitors cyclosporine A and NV556 decrease mitochondrial Ca2+ uptake in Tfam KO muscles and prolong the lifespan of Tfam KO mice.".
For more information about Targeting Mitochondria 2018, please visit www.targeting-mitochondria.com
Reversing wrinkled skin and lost hair in mice by restoring mitochondrial function
Prof. Keshav K. Singh from University of Alabama at Birmingham, USA will join the 9th World congress on Targeting Mitochondria which will be held in Berlin, in October 23-25, 2018 and give presentation entitled "Reversing wrinkled skin and lost hair in mice by restoring mitochondrial function".
Summary of presentation: "Our studies show that ubiquitous mitochondrial dysfunction in mice leads to predominant and profound effects on the skin resulting in wrinkles and visual hair loss with an increased number of dysfunctional hair follicles and inflammatory responses. Development of skin wrinkle was associated with the significant epidermal hyperplasia, hyperkeratosis, increased expression of matrix metalloproteinases and decreased expression of matrix metalloproteinase inhibitor. Surprisingly restoring mitochondrial function in mice reversed skin to normal and restored hair. To our knowledge that restoration of mitochondrial functions can reverse the skin and hair pathology is unprecedented."
If you would like to know more about Targeting Mitochondria Congress: www.targeting-mitochondria.com
Using live imaging to investigate the causes and consequences of mitochondrial toxicity in the kidney
Dr Andrew Hall from University of Zurich, Switzerland will participate to the congresss and talk about "Using live imaging to investigate the causes and consequences of mitochondrial toxicity in the kidney" during the 9th World Congress on Targeting Mitochondria 2018 which will be held in Berlin next October 23-25.
Dr. Andrew Hall summarized their team's research on Mitochonddria as: "Mitochondrial toxicity from therapeutic drugs is a common cause of acquired kidney disease in humans, but in most cases the pathogenic mechanisms are not well understood. Our group uses live imaging techniques, including intravital microscopy, and computational analysis to investigate how toxins alter mitochondrial function and dynamics in kidney tubular cells in real-time, and the downstream consequences of mitochondrial dysfunction on important physiological processes, such as solute transport and calcium signaling."
If you would like to know more about Targeting Mitochondria Congress: www.targeting-mitochondria.com
Phase 2 motor study of Omaveloxolone in patients with mitochondrial myopathies
Prof. John Vissing from Copenhagen University, Copenhagen, Denmark will participate to the 9th World Congress on Targeting Mitochondria, which will be held at Steigenberger Hotel, Berlin on October 23-25, 2018 and talk about "Phase 2 motor study of Omaveloxolone in patients with mitochondrial myopathies".
According to the Prof. Vissing:
"Nrf2 is the key endogenous regulator of cellular antioxidant response. Omaveloxone activates Nrf2 and the antioxidant response. In a placebo-controlled, double-blind, dose-escalating trial, sponsored by Reata Pharmaceutical, we explored the effect and safety of this drug in 54 patients with genetically confirmed mitochondrial myopathy. Results from the trial will be discussed"
For more information about Targeting Mitochondria 2018, www.targeting-mitochondria.com
Mitochondrial potassium channels: new regulation mechanism?
Prof. Adam Szewczyk from Nencki Institute of Experimental Biology, Warsaw, Poland will present study on "Mitochondrial potassium channels: new regulation mechanism?" during the Mitochondria congress which will be held in October 23-25, 2018, at Berlin, Germany.
Prof. Szewczyk will present the most interesting issues regarding function, regulation and pharmacology of the mitochondrial potassium channels. There are eight potassium channels known to contribute to the potassium permeability of the inner mitochondrial membrane: ATP-regulated channel, calcium-regulated channels of large, intermediate and small conductance, voltage-regulated Kv1.3 and Kv7.4 channels, two-pore-domain TASK-3 channel and SLO2 channel. The primary function of the mitochondrial potassium channels is regulation of the mitochondrial membrane potential. Additionally, mitochondrial potassium channels alter cellular respiration, regulation of the mitochondrial volume and ROS synthesis.
For more information about Targeting Mitochondria 2018, www.targeting-mitochondria.com
For more information about confirmed speakers: https://targeting-mitochondria.com/mitochondria-2018-speakers
The mitochondrial link to cocaine addiction: recent scientific advances
Mary Kay Lobo from University of Maryland School of Medicine, Baltimore, USA will talk about "The mitochondrial link to cocaine addiction: recent scientific advances" during the 9th World Congress on Targeting Mitochondria 2018 which will be held in Berlin next October 23-25.
If you would like to know more about Targeting Mitochondria Congress: www.targeting-mitochondria.com
Metabolic switches saving mitochondria from oxidative stress
Prof. Carsten Culmsee from Universität Marburg, Marburg, Germany will participate again in the Targeting Mitochindria 2018 congress and will talk about "Metabolic switches saving mitochondria from oxidative stress".
During the congress, Prof. Culmsee will present several examples of pharmacological and genetic approaches inducing bioenergetic switches from mitochondrial respiration to glycolysis which increase mitochondrial and cellular resilience against oxidative stresswith relevance to human diseases involving neurodegeneration and neuroinflammation.
For more information about Targeting Mitochondria 2018, please visit www.targeting-mitochondria.com
How to utilize a human hepatoma cell line to study off-target effects of drugs on mitochondrial DNA maintenance and bioenergetics?
The next 9th World Congress on Targeting Mitochondria, will welcome Dr Matthew J. Young from SIU School of Medicine in Carbondale, USA to talk about “Utilizing a human hepatoma cell line to study off-target effects of drugs on mitochondrial DNA maintenance and bioenergetics”.
According to Dr Young: "Evidence suggests anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) block the DNA synthesis activity of human DNA polymerases localized to mitochondria. Mitochondrial DNA (mtDNA) maintenance is important as mtDNA damage can induce cell death. Recently, NRTI drugs have been proposed to have anti-cancer properties. We are currently using a human hepatoma-derived cell line to investigate effects of drugs on cellular viability, bioenergetics, and mtDNA maintenance”.
Targeting Mitochondria 2018
October 23-25, 2018 - Berlin, Germany
www.targeting-mitochondria.com
The legal framework for mitochondrial therapy will be presented during Targeting Mitochondria Congress
Dr. Timo Faltus from the Martin-Luther-University Halle-Wittenberg, Germany will give a presentation entitled “The legal framework for mitochondrial therapy : Identifying and preventing legal pitfalls within the translation from bench to bedside” during the 9th World Congress on Targeting Mitochondria, which will be held at Steigenberger Hotel, Berlin on October 23-25, 2018.
According to Dr. Timo Faltus: "The therapeutic implementation of the various approaches of mitochondrial therapy is, irrespective of the therapeutic options, in the European Union and especially in Germany legally problematic. Certain versions of mitochondrial therapy may even be legally prohibited. These legal uncertainties and hurdles put successful translation of mitochondrial therapy at risk overall. Therefore, scientists should consider the issues of lawful development of mitochondrial therapy timely. The presentation will give an overview on the various legal questions of mitochondrial therapy from bench to bedside and will make scientists aware of legal pitfalls, to promote a successful translation of mitochondrial therapy".
Dr. Timo Faltus holds an Diploma of Biology (equivalent to a Master's degree) and a Diploma of Law, both from Goethe University Frankfurt, Germany. He also holds a doctorate of laws from Martin-Luther-University Halle-Wittenberg, Germany.
Currently, Timo leads the interdisciplinary research project GenomELECTION, which i.a. is concerned with the legal issues of genome editing. In addition, he collaborates with several research projects that develop cell-based therapies for various indications. In particular, Timo has specialized in regulatory issues of cell therapy, gene therapy, point-of-care therapy, and the use of medical devices to manufacture cell-derived pharmaceuticals within medical practices and hospitals.
For more information about Targeting Mitochondria 2018, please visit www.targeting-mitochondria.com
Modulation of cytochrome C oxidase activity to attenuate brain ischemia/reperfusion injury
Prof. Maik Hüttemann from the Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, USA will give a presentation entitled “Therapeutic application of specific near-infrared light wavelengths that inhibit cytochrome c oxidase results in robust neuroprotection” during the 9th World Congress on Targeting Mitochondria, which will be held at Steigenberger Hotel, Berlin on October 23-25, 2018.His research focuses cytochrome c oxidase (COX) and the small electron carrier cytochrome c (Cytc), which together catalyze the terminal reaction of the electron transport chain. His group studies basic processes, such as cell signaling pathways that act on COX and Cytc, which are often dysregulated in human diseases and under cellular stress conditions. His translational interest is geared toward the development of a new and non-invasive technology for the treatment of ischemia-reperfusion injury using infrared light.
Targeting mitochondrial metabolism, geroprotection to treating Alzheimer’s disease
Dr. Antonio Currais from The Salk Institute for Biological Studies, La Jolla, USA will give a presentation about "Targeting mitochondrial metabolism, geroprotection to treating Alzheimer’s disease" during the 9th World Congress on Targeting Mitochondria, which will be held at Steigenberger Hotel, Berlin on October 23-25, 2018.
According to Dr Currais: "In light of the consistent failures in clinical trials for Alzheimer's disease (AD), there is an urgent need to understand the primary mechanisms driving the disease and to identify new drug targets based upon this information. Age is by far the greatest risk factor for AD and related dementias. Using a set of compounds that we developed to purposely target features of the aging brain, we have identified a unique anti-aging and neuroprotective molecular pathway that is associated with the enhancement of mitochondrial metabolism and stability over time. The implications of our findings to the fields of aging, AD and mitochondria will be presented and discussed."
For more information, please visit www.targeting-mitochondria.com
Cellomics of mitochondrial morphofunction: presentation of the recent advances
During the 9th World Congress on Targeting Mitochondria 2018 which will be held in Berlin next October 23-25, Prof. Werner Koopman from RadboudUMC University, Nijmegen, The Netherlands will present a strategic talk about Cellomics of mitochondrial morphofunction.
According to Prof Koopman: "Mutations in NADH:ubiquinone oxidoreductase (complex I or CI), the first complex of the mitochondrial oxidative phosphorylation (OXPHOS) system, induce Leigh syndrome (LS) leading to early death in children. The LS pathomechanism is still poorly understood and effective treatment options are still lacking. Here we applied high content microscopy analysis (cellomics) to investigate the hypothesis that LS fibroblasts display “reductive stress” and that this stress impacts on cell viability and bioenergetics."
If you would like to know more about Targeting Mitochondria Congress: www.targeting-mitochondria.com
Targeting Mitochondria Congress 2018 will be held in Berlin in October 23-25, 2018
The Scientific Committee of the World Mitochondria Society is under preparation of the 9th World Congress on Targeting Mitochondria which will be held in Berlin on October 23-25, 2018.
All the information will be added on this website soon.
If you are interested to receive all the information about the World Mitochondria Society and Targeting Mitochondria 2018, please subscribe to WMS newsletter by clicking here.
Source for picture: Flixbus
Concluding remarks of Targeting Mitochondria 2017 by Prof. Volkmar Weissig
The 8th World Congress on Targeting Mitochondria was again this year organized in Berlin on October 23-24, 2017. The 8th edition was an excellent platform, this year for 273 participants from 44 countries, to share data, ideas, critical comments and opinions alike.
More Articles...
- Who attended Targeting Mitochondria 2017?
- How to evaluate mitochondrial function/dysfunction: from the bench to the bedside
- The scientific committee published the oral communications presented during Mitochondria Congress 2017
- Presentation of novel mechanisms of mitochondrial damage in oxidative death signaling are key targets for neuroprotective strategies
